Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations

HIV Clinical Trials
Don E SmithJohn Ray

Abstract

Atazanavir (ATV) is recommended to be dosed at 400 mg once daily or 300 mg daily coadministered with 100 mg ritonavir (RTV). 31 male patients receiving ATV either alone or boosted with RTV for more than 2 weeks had ATV concentration measured by high performance liquid chromatography (HPLC). ATV concentrations were adjusted to obtain a 24-hour trough level using a standard pharmacokinetic formula. 25 samples were taken from patients who received 300 mg ATV, 6 with 200 mg, 3 with 400 mg, and 2 with 150 mg, all boosted with 100 mg RTV. In the unboosted group, patients received 400 mg (7) or 600 mg (2). The median adjusted 24-hour trough ATV concentration was 630 ng/mL (interquartile range [IQR] 355-1034) in the boosted and 113 ng/mL (IQR 50-225) in the unboosted group (p = .001). Median serum bilirubin concentration was 34 IU/L (IQR 27.5-49) and 41 IU/L (IQR 31-45) in the boosted and unboosted groups, respectively. In the boosted group, high ATV concentrations were significantly correlated with increased serum bilirubin concentrations (p = .003). ATV concentrations showed considerable interpatient variability. Bilirubin concentrations are an indicator of high ATV concentrations and may prove to be useful in selecting patients for ...Continue Reading

References

Jan 1, 1979·Cancer Chemotherapy and Pharmacology·D S AlbertsJ F Gross
May 25, 2004·Antimicrobial Agents and Chemotherapy·Anne-Marie TaburetPierre-Marie Girard
May 29, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Robin WoodMichael Giordano
Jul 14, 2004·JAMA : the Journal of the American Medical Association·Patrick G YeniPaul A Volberding
Jun 2, 2005·Journal of Pharmaceutical and Biomedical Analysis·Estelle CateauNicolas Venisse
Apr 13, 2006·Sexual Health·Sarangapany JeganathanJulian Gold

❮ Previous
Next ❯

Citations

Aug 1, 2007·European Journal of Clinical Pharmacology·Nils von HentigSebastian Harder
Nov 21, 2007·Antimicrobial Agents and Chemotherapy·Jennifer J KiserUNKNOWN Adolescent Trials Network for HIV/AIDS Interventions
Oct 13, 2006·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·M Hartmann
Mar 31, 2010·Expert Opinion on Drug Safety·Xia LiuFujie Zhang
Aug 9, 2011·Thérapie·Caroline SolasUNKNOWN Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique
Apr 16, 2011·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Laurent MandelbrotGilles Peytavin
Jan 2, 2009·Clinical Pharmacology and Therapeutics·A AvihingsanonK Ruxrungtham
Sep 1, 2007·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Stefan EsserStephan Grabbe
Nov 3, 2011·Fundamental & Clinical Pharmacology·Dario CattaneoEmilio Clementi
Jan 8, 2011·Fundamental & Clinical Pharmacology·Dario CattaneoEmilio Clementi
Nov 19, 2013·Journal of Clinical Pharmacology·Roberto LozanoAlberto-Fermín Apesteguia
Dec 28, 2010·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·Ana P Nso RocaMaria Isabel de José
Oct 26, 2016·Fundamental & Clinical Pharmacology·David MetsuPeggy Gandia
Jun 30, 2011·Journal of Pharmacy Practice·Rustin D CrutchleyGene D Morse
Dec 4, 2009·The Annals of Pharmacotherapy·Amanda Caroline JacquesCharles J L la Porte
Jun 22, 2010·AIDS Research and Human Retroviruses·Keith W CrawfordUNKNOWN AIDS Clinical Trials Protocol 5015 Team
Nov 30, 2011·Antimicrobial Agents and Chemotherapy·Jeff East, Lucas Scott Blanton
Apr 18, 2009·Current Opinion in HIV and AIDS·Matthijs van LuinDavid M Burger
Jul 23, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Gopal KrishnaJ McLeod
May 29, 2019·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Heidi M CraneJoseph A C Delaney
Jul 2, 2014·The Pediatric Infectious Disease Journal·Torsak BunupuradahThanyawee Puthanakit
Apr 23, 2019·Therapeutic Drug Monitoring·Hylke WaalewijnUNKNOWN Pediatric Antiretroviral Working Group (PAWG)
Jun 6, 2009·Drugs·Katherine F CroomSusan J Keam
Nov 28, 2020·Virology Journal·Mohamed MahdiJózsef Tőzsér
Dec 1, 2008·Enfermedades infecciosas y microbiología clínica·Luis F López-Cortés

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.